Phibro raises FY 2025 guidance with Zoetis portfolio integration driving 25% revenue growth
Q2 2025 Management View CEO Jack Bendheim noted that this was "one of the strongest quarters since going public," highlighting the successful integration of the Zoetis Medicated Feed Additive (MFA) ...
Embecta raises FY2025 adjusted EBITDA margin guidance to 37% amid cost-cutting and debt reduction focus
Q1 2025 Management View CEO Dev Kurdikar emphasized the company's pivot to the next phase of transformation, focusing on three priorities: strengthening the core business, expanding the product ...